Atlas Trials

Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Clinical trial NCT03719313 · COMPLETED

Trial details

NCT number
NCT03719313
Sponsor
Eiger BioPharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Hepatitis Delta Virus
Start date
2018-12-01
Primary completion
2022-10-06
Enrollment
407

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.